Phase I/II dose escalation and cohort expansion of safety and tolerability study of intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in patients with MM. This evidence concerns the gene CD40 and Miyoshi myopathy.